NCT06601140 (EMC1) is a NA clinical trial of EMOCARE software in Major Depressive Disorder (MDD), sponsored by Emobot.

Who is sponsoring NCT06601140?

NCT06601140 is sponsored by Emobot.

What drugs are being tested in NCT06601140?

Interventions in NCT06601140: EMOCARE software.

What condition does NCT06601140 study?

NCT06601140 studies Major Depressive Disorder (MDD).

Is NCT06601140 still recruiting?

NCT06601140 is currently recruiting now. Last updated 19 February 2026.

Last reviewed 2026-02-19 · How we verify

NCT06601140: EMC1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode

Recruiting now NA Last updated 19 February 2026

What this trial tests

NA trial testing EMOCARE software in Major Depressive Disorder (MDD) in 104 participants. Currently enrolling.

Timeline

5 March 2025

Primary endpoint
4 February 2027

4 February 2027

Quick facts

Lead sponsor	Emobot
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	104
Start date	5 March 2025
Primary completion	4 February 2027
Estimated completion	4 February 2027
Sites	11 locations across France

Drugs / interventions tested

EMOCARE software

Conditions studied

Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →

Sponsor

Emobot

Who can join

18 and older, any sex, with Major Depressive Disorder (MDD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from mild to moderately severe depressive episod. It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of patient). The main questions it aims to answer are as follows: Does EMOCARE provide consistent results compared with tools already used in current practice? What are the medical problems encountered by participants when using EMOCARE? The researchers will compare EMCOCARE to various questionnaires usually used in the management of patients suffering from depression (PHQ-9, MADRS, GAD-7, BDI-II, EQ-5D-5L). Participants who agree to take part in the study, during a selection visit, will be able to: 1. Install the software on a digital interface (smartphone, computer, etc.) and activate or deactivate it whenever they wish during the 6-week follow-up period. 2. Attend 2 scheduled appointments at the centre (a first appointment then a second 6 weeks later) to complete a series of questionnaires, being questioned by the doctor, and fill in other questionnaires on their own. 3. At home, answer questionnaires independently, 2 weeks and 4 weeks after the first appointment. 4. Receive a telephone call from the doctor 3 weeks after the first appointment to find out how the participants are feeling. 5. Keep a diary with the symptoms they have experienced, any medical consultations they have made, or changes in drug treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder (MDD)

Currently open trials in the same condition.

NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
NCT07294924 — Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements · recruiting

Other Emobot trials

Trials by the same sponsor.

NCT06860165 — Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression · recruiting
NCT05988840 — Acquisition and Analysis of Relationships Between Longitudinal Emotional Signals Produced by an Artificial Intelligence · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06601140 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emobot
Last refreshed: 19 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06601140.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing